Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Chen, Yi-Chuna; 1 | Chiu, Ya-Jenb; 1 | Lin, Chih-Hsina | Hsu, Wen-Chuina; c | Wu, Jia-Lub | Huang, Chen-Hsiangb | Lin, Chia-Weib | Yao, Ching-Fad | Huang, Hei-Jene | Lo, Yen-Shia | Chen, Chiung-Meia | Wu, Yih-Rua | Chang, Kuo-Hsuana; * | Lee-Chen, Guey-Jenb; * | Mei Hsieh-Li, Hsiub; *
Affiliations: [a] Department of Neurology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan | [b] Department of Life Science, National Taiwan Normal University, Taipei, Taiwan | [c] Dementia Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan | [d] Department of Chemistry, National Taiwan Normal University, Taipei, Taiwan | [e] Department of Nursing, Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan
Correspondence: [*] Correspondence to: Kuo-Hsuan Chang, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan. E-mail: [email protected] and Guey-Jen Lee-Chen and Hsiu Mei Hsieh-Li, National Taiwan Normal University, Taipei 11677, Taiwan. E-mails: [email protected] (G.-J. Lee-Chen) and [email protected] (H.M. Hsieh-Li).
Note: [1] These authors contributed equally to this work.
Abstract: Alzheimer’s disease (AD), associated with abnormal accumulation of amyloid-β (Aβ), is the most common cause of dementia among older people. A few studies have identified substantial AD biomarkers in blood but their results were inconsistent. Here we screened gene expression alterations on Aβ-GFP SH-SY5Y neuronal model for AD, and evaluated the findings on peripheral leukocytes from 78 patients with AD and 56 healthy controls. The therapeutic responses of identified biomarker candidates were further examined in Aβ-GFP SH-SY5Y neuronal and APP/PS1/Tau triple transgenic (3×Tg-AD) mouse models. Downregulation of apolipoprotein E (APOE) and tropomyosin receptor kinase A (TRKA) were detected in Aβ-GFP SH-SY5Y cells and validated by peripheral leukocytes from AD patients. Treatment with an in-house indole compound NC009-1 upregulated the expression of APOE and TRKA accompanied with improvement of neurite outgrowth in Aβ-GFP SH-SY5Y cells. NC009-1 further rescued the downregulated APOE and TRKA and reduced Aβ and tau levels in hippocampus and cortex, and ameliorated cognitive deficits in streptozocin-induced hyperglycemic 3×Tg-AD mice. These results suggest the role of APOE and TRKA as potential peripheral biomarkers in AD, and offer a new drug development target of AD treatment. Further studies of a large series of AD patients will be warranted to verify the findings and confirm the correlation between these markers and therapeutic efficacy.
Keywords: Alzheimer’s disease, amyloid-β, APOE, biomarker, indole compound, TRKA
DOI: 10.3233/JAD-180643
Journal: Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 737-756, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]